Clinical Trial Update: The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of cediranib (AZD2171) in patients with non-small cell lung cancer and head and neck cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Cediranib (AZD2171) (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2013-10-17